Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial

References

1. 1.↵
   2. Adel Fahmideh M,
   3. Scheurer ME

   . Pediatric brain tumors: descriptive epidemiology, risk factors, and future directions. cancer epidemiology. Cancer Epidemiol Biomarkers Prev 2021;30:813–21 doi:10.1158/1055-9965.EPI-20-1443 pmid:33653816

   Abstract/FREE Full Text
2. 2.↵
   2. Ryall S,
   3. Zapotocky M,
   4. Fukuoka K, et al

   . Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 2020;37:569–83.e5 doi:10.1016/j.ccell.2020.03.011 pmid:32289278

   CrossRefPubMed
3. 3.↵
   2. Lhermitte B,
   3. Wolf T,
   4. Chenard MP, et al

   . Molecular heterogeneity in BRAF-mutant gliomas: diagnostic, prognostic, and therapeutic implications. Cancers (Basel) 2023;15:1268 doi:10.3390/cancers15041268 pmid:36831610

   CrossRefPubMed
4. 4.↵
   2. D'Arco F,
   3. Culleton S,
   4. De Cocker LJL, et al

   . Current concepts in radiologic assessment of pediatric brain tumors during treatment, part 1. Pediatr Radiol 2018;48:1833–43 doi:10.1007/s00247-018-4194-9 pmid:29980859

   CrossRefPubMed
5. 5.↵
   2. Fangusaro J,
   3. Witt O,
   4. Hernáiz Driever P, et al

   . Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 2020;21:e305–16 doi:10.1016/S1470-2045(20)30064-4 pmid:32502457

   CrossRefPubMed
6. 6.↵
   2. D’Arco F,
   3. O'Hare P,
   4. Dashti F, et al

   . Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements. Neuroradiology 2018;60:427–36 doi:10.1007/s00234-018-1979-3 pmid:29383433

   CrossRefPubMed
7. 7.↵
   2. Chappell R,
   3. Miranpuri SS,
   4. Mehta MP

   . Dimension in defining tumor response. J Clin Oncol 1998;16:1234 doi:10.1200/JCO.1998.16.3.1234 pmid:9508213

   CrossRefPubMed
8. 8.↵
   2. Gahrmann R,
   3. van den Bent M,
   4. van der Holt B, et al

   . Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial. Neuro Oncol 2017;19:853–61 doi:10.1093/neuonc/now311 pmid:28204639

   CrossRefPubMed
9. 9.↵
   2. Gahrmann R,
   3. Smits M,
   4. Vernhout RM, et al

   . The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab. Neurooncol Adv 2022;4:vdac032 doi:10.1093/noajnl/vdac032 pmid:35419519

   CrossRefPubMed
10. 10.↵
    2. Huang RY,
    3. Unadkat P,
    4. Bi WL, et al

    . Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro Oncol 2019;21:234–41 doi:10.1093/neuonc/noy126 pmid:30085283

    CrossRefPubMed
11. 11.↵
    2. Ellingson BM,
    3. Kim GH,
    4. Brown M, et al

    . Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: evidence from a phase I trial of ivosidenib. Neuro Oncol 2022;24:770–78 doi:10.1093/neuonc/noab256 pmid:34751786

    CrossRefPubMed
12. 12.↵
    2. Nicolaides T,
    3. Nazemi KJ,
    4. Crawford J, et al

    . Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget 2020;11:1942–52 doi:10.18632/oncotarget.27600 pmid:32523649

    CrossRefPubMed
13. 13.↵
    2. Weinberg BD,
    3. Gore A,
    4. Shu HK, et al

    . Management-based structured reporting of posttreatment glioma response with the Brain Tumor Reporting and Data System. J Am Coll Radiol 2018;15:767–71 doi:10.1016/j.jacr.2018.01.022 pmid:29503151

    CrossRefPubMed
14. 14.↵
    2. Aboian M,
    3. Bousabarah K,
    4. Kazarian E, et al

    . Clinical implementation of artificial intelligence in neuroradiology with development of a novel workflow-efficient picture archiving and communication system-based automated brain tumor segmentation and radiomic feature extraction. Front Neurosci 2022;16:860208 doi:10.3389/fnins.2022.860208 pmid:36312024

    CrossRefPubMed
15. 15.↵
    2. Robin X,
    3. Turck N,
    4. Hainard A, et al

    . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77 doi:10.1186/1471-2105-12-77 pmid:21414208

    CrossRefPubMed
16. 16.↵
    2. Brüningk SC,
    3. Peacock J,
    4. Whelan CJ, et al

    . Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep 2021;11:20219 doi:10.1038/s41598-021-99507-2 pmid:34642366

    CrossRefPubMed
17. 17.↵
    2. Glazar DJ,
    3. Grass GD,
    4. Arrington JA, et al

    . Tumor volume dynamics as an early biomarker for patient-specific evolution of resistance and progression in recurrent high-grade glioma. J Clin Med 2020;9:2019 doi:10.3390/jcm9072019

    CrossRef
18. 18.↵
    2. Tsai JW,
    3. Choi JJ,
    4. Ouaalam H, et al

    . Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment. Neurooncol Adv 2023;5:vdac182 doi:10.1093/noajnl/vdac182 pmid:36926246

    CrossRefPubMed
19. 19.↵
    2. Bø HK,
    3. Solheim O,
    4. Jakola AS, et al

    . Intra-rater variability in low-grade glioma segmentation. J Neurooncol 2017;131:393–402 doi:10.1007/s11060-016-2312-9 pmid:27837437

    CrossRefPubMed
20. 20.↵
    2. Kazerooni AF,
    3. Khalili N,
    4. Liu X, et al

    . The Brain Tumor Segmentation (BraTS) Challenge 2023: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs). ArXiv 2024 Jan 4. [Epub ahead of Print] arXiv:2305.17033v2 pmid:37292481

    PubMed